US-based PacBio has entered into a joint research agreement with France-based TychoBio on AI-driven drug discovery for rare diseases. The companies will use PacBio’s HiFi sequencing and Kinnex to obtain training data for AI models and aim to create SBOs.
US-based PacBio announced on 6 October 2026 that it had entered into a joint research agreement with France-based TychoBio for rare disease therapeutics. TychoBio plans to use PacBio’s HiFi sequencing and Kinnex to obtain training data for AI models.
The companies aim to build high-performance models through AI training and create steric-blocking antisense oligonucleotides (SBOs), whose safety and efficacy can be rigorously controlled.
The initiative seeks to establish a new data foundation for AI-driven drug discovery for rare diseases. Attention is focused on whether the companies’ joint research will lead to concrete clinical applications.